Skip to main content

Nurix Therapeutics, Inc.

corporate_fare Company Profile

Nurix Therapeutics, Inc.

NRIX·NASDAQ·Life Sciences·CIK 0001549595

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing, and selling targeted protein degradation medicines for cancer and inflammatory diseases. The company uses an artificial intelligence (AI)-integrated discovery engine and expertise in ligase to translate protein degradation science into clinical advancements. Nurix's wholly owned clinical pipeline includes three investigational drug candidates: bexobrutideg (NX-5948), a selective degrader of Bruton's tyrosine kinase (BTK); zelebrudomide (NX-2127), a dual degrader of BTK and transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase. The company is also developing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix's partnered drug discovery pipeline includes a clinical stage degrader of IRAK4 (NX-0479/GS-6791), a preclinical stage degrader of STAT6, and multiple undisclosed targets under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A., and Pfizer Inc. Nurix retains certain options for co-development, co-commercialization, and profit sharing in the United States for multiple drug candidates within these collaborations. Both wholly owned and partnered pipelines are powered by the DEL-AI discovery engine, which uses machine learning for DNA encoded library (DEL) hit-finding, degrader design, automated chemistry synthesis, and direct-to-biology screening and optimization to generate new chemical entity drug candidates.

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for NRIX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Nurix Therapeutics Details Strong Clinical Progress for Lead Candidates & Substantial Funding in Annual Report
  • Nurix Therapeutics Reports Strong Bexobrutideg Phase 1 Data, Initiates Pivotal Phase 2, and Plans Phase 3 Trial
  • Nurix Therapeutics Initiates Pivotal Phase 2 for Bexobrutideg in CLL, Reports Strong Data & Outlines 2026 Goals

Financial Snapshot

Fiscal year ended November 30, 2025
Revenue
$83.98M
Net Income
-$264.46M
Diluted EPS
-$3.05
Op. Cash Flow
-$249.47M
Free Cash Flow
-$263.47M
Operating Income
-$285.67M
Cash & Equivalents
$246.96M
Debt / Equity
0.00×
Net Margin
-314.9%
Shares Outstanding
101.81M sh
Source: 10-K · filed 2026-01-28 · accession 0001549595-26-000016
$12.85
52-week range · as of 2026-11-03 $11.67 – $28.23
Market cap
$1.4B
Volume
2.4M (0.7× avg)
3-mo avg 3.6M
Live data · 2026-11-22 12:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NRIX - Filings & News (Page 2)

NRIX
Jan 28, 2026, 4:09 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $17.87
Real-time Price: $12.85 info
Change: -$5.02 (-28%) info
Market Cap: $1.404B info
NRIX
Jan 28, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $17.87
Real-time Price: $12.85 info
Change: -$5.02 (-28%) info
Market Cap: $1.404B info
NRIX
Jan 12, 2026, 8:34 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $19.49
Real-time Price: $12.85 info
Change: -$6.64 (-34%) info
Market Cap: $1.404B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets